Barbara O’Brien, MD retweetledi

There are so few trials which enroll patients with LMD. So glad to demonstrate benefit with the HER2CLIMB regimen including meaningful improvements in neuro deficits and quality of life. Inclusion ➡️ progress.
Paolo Tarantino@PTarantinoMD
Results from @TheTBCRC 049 trial of tucatinib/cape/trastuzumab for HER2+ LMD now published in @NatureCancer. Most patients had improved neurological deficits, PFS was 4.4 months and OS 10 months, with 41% of patients alive at 18 months. nature.com/articles/s4301…
English



